Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 3—March 2007

Research

Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1

Stephen Mark Tompkins*1Comments to Author , Zi-Shan Zhao*, Chia-Yun Lo*, Julia A. Misplon*, Teresa Liu*, Zhiping Ye*, Robert J. Hogan†, Zhengqi Wu*, Kimberly A. Benton*, Terrence M. Tumpey‡, and Suzanne L. Epstein*
Author affiliations: *Food and Drug Administration, Bethesda, Maryland, USA; †University of Georgia, Athens, Georgia, USA; ‡Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Figure 5

Results of vaccination and booster with DNA prime–adenovirus (Ad), showing cross-protection. Mice (8–10 per group) were immunized as in Figure 4 or intranasally given a sublethal priming infection with A/PR/8. Three weeks later they were challenged with a high dose of A/PR/8 (1.5x 104 50% lethal dose [LD50]) or moderate dose of A/FM (10 LD50) and monitored for survival. The cumulative survival rate for mice immunized with A/PR/8 and M2-DNA+M2-Ad was significantly higher than that for mice immuni

Figure 5. Results of vaccination and booster with DNA prime–adenovirus (Ad), showing cross-protection. Mice (8–10 per group) were immunized as in Figure 4 or intranasally given a sublethal priming infection with A/PR/8. Three weeks later they were challenged with a high dose of A/PR/8 (1.5x 104 50% lethal dose [LD50]) or moderate dose of A/FM (10 LD50) and monitored for survival. The cumulative survival rate for mice immunized with A/PR/8 and M2-DNA+M2-Ad was significantly higher than that for mice immunized with B/NP-DNA+B/NP-Ad (p<0.001, log rank). Data are representative of multiple experiments.

Main Article

1Current affiliation: University of Georgia, Athens, Georgia, USA

TOP